XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Components
6 Months Ended
Jun. 30, 2023
Balance Sheet Components  
Balance Sheet Components

6. Balance Sheet Components

Allowance for doubtful accounts

The following is a roll-forward of the allowances for doubtful accounts related to trade accounts receivable for the three and six months ended June 30, 2023 and 2022:

Three Months Ended

    

June 30, 

2023

2022

(in thousands)

Beginning balance

$

5,134

$

2,392

Provision for doubtful accounts

446

1,170

Write-offs

(1)

Total

$

5,580

$

3,561

Six Months Ended

    

June 30, 

2023

2022

(in thousands)

Beginning balance

$

3,830

$

2,429

Provision for doubtful accounts

1,750

1,501

Write-offs

(369)

Total

$

5,580

$

3,561

Property and Equipment, net

The Company’s property and equipment consisted of the following:

June 30, 

December 31, 

Useful Life

2023

    

2022

(in thousands)

Machinery and equipment

3-5 years

$

78,705

$

66,262

Computer equipment

3 years

1,701

 

1,308

Purchased and capitalized software held for internal use

3 years

6,739

5,464

Leasehold improvements

Lesser of useful life or lease term

29,806

 

29,747

Construction-in-process

31,091

 

25,370

148,042

 

128,151

Less: Accumulated depreciation and amortization

(45,121)

 

(35,698)

Total Property and Equipment, net

$

102,921

$

92,453

The Company’s long-lived assets are mostly located in the United States.

During the six months ended June 30, 2023, the increase in net property and equipment was due to expansion projects and purchases of new equipment for the Company’s laboratories located in Texas and California to expand testing capabilities, offset by depreciation expense of $10.2 million recorded in the six months ended June 30, 2023. Depreciation expense of $7.3 million was recorded in the six months ended June 30, 2022. The Company did not incur any impairment charges during the six months ended June 30, 2023 or 2022.

Other Accrued Liabilities

The Company’s other accrued liabilities consisted of the following:

June 30, 

    

December 31, 

2023

    

2022

(in thousands)

Reserves for refunds to insurance carriers

$

15,480

$

18,948

Accrued charges for third-party testing

9,401

17,036

Testing and laboratory materials from suppliers

13,493

13,281

Marketing and corporate affairs

9,822

8,943

Legal, audit and consulting fees

36,343

 

36,710

Accrued shipping charges

1,294

485

Sales and income tax payable

4,624

4,319

Accrued third-party service fees

6,890

6,631

Clinical trials and studies

 

11,371

23,301

Operating lease liabilities, current portion

10,435

7,639

Property and equipment purchases

3,148

1,821

Other accrued interest

1,078

1,078

Other accrued expenses

 

2,134

4,022

Total other accrued liabilities

$

125,513

$

144,214

 

Reserves for refunds to insurance carriers include overpayments from and amounts to be refunded to insurance carriers, and additional amounts that the Company estimates for potential refund requests during the period. When the Company releases these previously accrued amounts, they are recognized as product revenues in the condensed statements of operations and comprehensive loss. The following table summarizes the reserve balance and activities for refunds to insurance carriers for the six months ending June 30, 2023 and 2022:

June 30, 

    

June 30, 

2023

    

2022

(in thousands)

Beginning balance

$

18,948

$

17,210

Additional reserves

 

5,148

 

8,576

Refunds to carriers

 

(963)

(793)

Reserves released to revenue

(7,653)

(9,081)

Ending balance

$

15,480

$

15,912